Pharmacogenomic (PGx) applications in the management of cardiovascular disease continue to emerge. Leading use cases for clinical translation into practice include clopidogrel (CYP2C19), warfarin (i.e., VKORC1, CYP2C9), and simvastatin (SLCO1B1). The clopidogrel-CYP2C19 drug-gene pair has been the most extensively studied with updated practice recommendations based on recently conducted prospective, randomized controlled trials. Despite the growing evidence, the clinical applications of PGx into cardiovascular practice remain limited.
Advances in the understanding of drug-gene pairs relevant to cardiology, and the ability to disseminate scientific findings into real-world practice are critical to advancing patient care. This research topic will present novel insights into the treatment of patients with cardiovascular disease who could benefit from PGx applications to achieve the promise of precision medicine.
Original research, review articles, and commentaries will be accepted. Sub-topics include but are not limited to:
-CYP2C19 genotyping to guide antiplatelet therapy in the setting of percutaneous coronary intervention and associated clinical outcomes
-Emerging and novel uses of CYP2C19 genotyping in cardiovascular practice (i.e., stroke, neurovascular, electrophysiology, etc.)
-Pharmacogenes relevant to warfarin dosing and outcomes for prevention and treatment of thromboembolism
-SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms
-Genome-wide association studies approaches to identify variants of interest that could affect cardiovascular medication response
-Novel and emerging cardiovascular drug gene-pairs of interest that have potential to impact variability in medication response or clinical outcomes
-Barriers and solutions for the implementation of cardiovascular pharmacogenomics into practice.
Keywords:
pharmacogenomics, cardiovascular, genotyping, antiplatelet, clopidogrel, CYP2C19, warfarin, anticoagulation, statins
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Pharmacogenomic (PGx) applications in the management of cardiovascular disease continue to emerge. Leading use cases for clinical translation into practice include clopidogrel (CYP2C19), warfarin (i.e., VKORC1, CYP2C9), and simvastatin (SLCO1B1). The clopidogrel-CYP2C19 drug-gene pair has been the most extensively studied with updated practice recommendations based on recently conducted prospective, randomized controlled trials. Despite the growing evidence, the clinical applications of PGx into cardiovascular practice remain limited.
Advances in the understanding of drug-gene pairs relevant to cardiology, and the ability to disseminate scientific findings into real-world practice are critical to advancing patient care. This research topic will present novel insights into the treatment of patients with cardiovascular disease who could benefit from PGx applications to achieve the promise of precision medicine.
Original research, review articles, and commentaries will be accepted. Sub-topics include but are not limited to:
-CYP2C19 genotyping to guide antiplatelet therapy in the setting of percutaneous coronary intervention and associated clinical outcomes
-Emerging and novel uses of CYP2C19 genotyping in cardiovascular practice (i.e., stroke, neurovascular, electrophysiology, etc.)
-Pharmacogenes relevant to warfarin dosing and outcomes for prevention and treatment of thromboembolism
-SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms
-Genome-wide association studies approaches to identify variants of interest that could affect cardiovascular medication response
-Novel and emerging cardiovascular drug gene-pairs of interest that have potential to impact variability in medication response or clinical outcomes
-Barriers and solutions for the implementation of cardiovascular pharmacogenomics into practice.
Keywords:
pharmacogenomics, cardiovascular, genotyping, antiplatelet, clopidogrel, CYP2C19, warfarin, anticoagulation, statins
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.